Journal article

Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants

Maria Ximena Rojas-Reyes, Colin J Morley, Roger Soll

COCHRANE DATABASE OF SYSTEMATIC REVIEWS | WILEY | Published : 2012

Abstract

BACKGROUND: Surfactant therapy is effective in improving the outcome of very preterm infants. Trials have studied a wide variety of surfactant preparations used either to prevent or treat respiratory distress syndrome (RDS). In animal models, prophylactic surfactant leads to more homogeneous distribution and less evidence of lung damage. However, administration requires intubation and treatment of infants who will not go on to develop RDS. This is of particular concern with the advent of improved approaches to providing continuous distending pressure, particularly in the form of nasal continuous positive airway pressure (CPAP). OBJECTIVES: To compare the effect of prophylactic surfactant adm..

View full abstract

Grants

Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA


Funding Acknowledgements

Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN267200603418C.Dr. MX Rojas has participated as co investigator of independent trials supported in part by Abbott Laboratories and Fisher and Pickell Ind.Internal sourcesPontificia Universidad Javeriana, Colombia. Support the time dedicated by Dr. Maria Rojas